Latest News and Press Releases

TEL-AVIV, Israel, July 14, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late...

The Phase III study with RHB-104 for Crohn's disease is currently ongoing in the U.S. and additional countries, with up to 120 clinical sites planned globally (the MAP US study) A Clinical...

Once granted, the two new U.S. patents covering RHB-104 are expected to be valid through 2029 RHB-104 is undergoing a first Phase III study for the treatment of Crohn's disease in the U.S....

The Phase I/II study, led by Dr. Chris Parsons, MD, associate professor at Louisiana State University Health Sciences Center, is intended to evaluate the safety and tolerability of ABC294640 in...

TEL-AVIV, Israel, June 16, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company focused on late clinical-stage,...

TEL-AVIV, Israel, June 16, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late...

TEL-AVIV, Israel, June 15, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company focused on late clinical-stage,...

Top-line results from the RHB-105 Phase III study demonstrated 89.4% efficacy in eradicating H. pylori infection with RHB-105 The Phase III study successfully met its primary endpoint of...

The last patient has been enrolled in the Phase IIa, proof-of-concept clinical study evaluating RHB-104 as an add-on therapy to interferon beta-1a in patients treated for relapsing-remitting...

Last patient has completed treatment course with RHB-105, for primary endpoint evaluation The Phase III top-line results with RHB-105 for the treatment of H. pylori bacterial infection are...